Patents by Inventor Matthew W. Boudreau

Matthew W. Boudreau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Activators of the unfolded protein response
    Patent number: 11584718
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: February 21, 2023
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
  • ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE
    Publication number: 20210340100
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Application
    Filed: May 13, 2021
    Publication date: November 4, 2021
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David J. SHAPIRO, Paul J. HERGENROTHER, Matthew W. BOUDREAU
  • ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE
    Publication number: 20210276951
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Application
    Filed: July 1, 2019
    Publication date: September 9, 2021
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David J. SHAPIRO, Paul J. HERGENROTHER, Matthew W. BOUDREAU
  • Activators of the unfolded protein response
    Patent number: 11046647
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: June 29, 2021
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
  • ACTIVATORS OF THE UNFOLDED PROTEIN RESPONSE
    Publication number: 20200190029
    Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.
    Type: Application
    Filed: February 26, 2020
    Publication date: June 18, 2020
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: David J. SHAPIRO, Paul J. Hergenrother, Matthew W. Boudreau